Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<p>Banoxantrone (BN) hypoxia modification is replicated in U87, a xenograft model with different growth and hypoxia characteristics. U87 xenografts were less hypoxic than Calu6 xenografts. The group average ΔR<sub>1</sub> for size matched (<b>A</b>) Calu6 was less than that for (<b>B</b>) U87 xenografts. Error bars are SEM. Significant difference between (<b>C</b>) group ΔR<sub>1</sub> and (<b>D</b>) group MRI hypoxic volume were observed between the two tumor models. Examining the U87 xenografts further, (<b>E</b>) U87 Cohort reduction in MRI hypoxic fraction was seen at day 3 in treated drug tumors, relative to control tumors (Cn; white bars), with (<b>F</b>) U87 example segmented MRI images showing hypoxic (blue), normoxic (yellow), and necrotic (gray) tumor. <b>G,</b> Lower percentage of pimonidazole staining was detected in drug-treated U87 tumors at day 3, compared to controls. <b>H,</b> Example pimonidazole adduct formation images (×40 magnification).</p>

Original publication

DOI

10.1158/2767-9764.27144149

Type

Other

Publication Date

01/10/2024